Skandinaviska Enskilda Banken (SEB)
DAWN

Skandinaviska Enskilda Banken (SEB)’s Day One Biopharmaceuticals DAWN Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.22M Buy
+150,000
New +$2.11M 0.07% 62
2025
Q1 		– Sell
-41,771
Closed -$525K – 848
2024
Q4 		$525K Buy
+41,771
New +$581K ﹤0.01% 708

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 26.7% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s DAWN Position: Q1 2026 in Review

Skandinaviska Enskilda Banken (SEB) opened a new position in Day One Biopharmaceuticals (DAWN) in Q1 2026: 150,000 shares worth $3.22M. The stake represents 0.07% of the portfolio and ranks #62 among its holdings. This is a return to the name: Skandinaviska Enskilda Banken (SEB) previously reported a position in DAWN as recently as Q4 2024.

Skandinaviska Enskilda Banken (SEB) first reported a position in DAWN in Q4 2024 and has held it in 2 quarters since. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Skandinaviska Enskilda Banken (SEB) held 150,000 shares of Day One Biopharmaceuticals worth $3.22M as of Q1 2026.
  • Day One Biopharmaceuticals was a new Skandinaviska Enskilda Banken (SEB) position in Q1 2026.
  • Day One Biopharmaceuticals made up 0.07% of Skandinaviska Enskilda Banken (SEB)'s portfolio in Q1 2026, its #62 holding.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Day One Biopharmaceuticals in Q4 2024 and has held it in 2 quarters since.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q1 2026, filed 15 May 2026.